Modified L-Asparaginase
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 62/523,061, filed Jun 21, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,174,302 | Modified L-Asparaginase In force · High confidence UsedRemaining | Jazz Pharmaceuticals Ireland Limited | In force | High confidence | ||
| US 11,802,279 | Modified L-Asparaginase In force · High confidence | Jazz Pharmaceuticals Ireland Ltd. | In force | High confidence | ||
| US 12,781,212 | Modified L-Asparaginase In force · High confidence | Jazz Pharmaceuticals Ireland Limited | In force | High confidence | ||
| Application 16/226,499 | Modified L-Asparaginase Abandoned Abandoned Oct 4, 2021 | Jazz Pharmaceuticals Ireland Ltd. | Abandoned | Abandoned Oct 4, 2021 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Jazz Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.